HOME >> BIOLOGY >> NEWS
Powerful ally in life sciences: UH research head to give keynote

HOUSTON, Feb. 6, 2007 Calling the University of Houston 'a powerful ally to the life science industry in our region,' BioHouston is featuring UH's new head of research, Donald L. Birx, as keynote speaker at its next breakfast forum Wednesday, Feb. 14.

BioHouston, a 501(c)(3) founded by regional academic and research institutions, is establishing the Houston region as a global competitor in life science and biotechnology commercialization and technology transfer to generate economic wealth for the area.

With nearly $75 million in annual research expenditures, researchers at UH collaborate with other Texas Medical Center institutions and regional biotechnology companies. Birx, vice chancellor for the UH System and vice president for research for UH, advocates collaborative strategic activities and research clusters that relate to and translate UH's research capabilities, as well as build on the strengths of the university and its community partners.

In his BioHouston talk 'Research Clusters and Industry Partnerships' Birx will outline the cutting-edge plans he has brought to Houston and the research under way at UH. In his address, he plans to cover how his 'clusters' approach translates to interdisciplinary research, UH's push for Tier I status, how his background in applied research and making marketable applications speaks to the areas of tech transfer and IP, and how his finance background enhances his role in managing scientific research endeavors. He also will elaborate on some of the particular cross-disciplinary research areas he sees as being especially dynamic at UH.

Birx holds a Ph.D. in electrical engineering from the University of Dayton, an M.B.A. in finance and M.S. in biophysics from Miami University in Ohio, and a B.S. in engineering physics from the University of California, Berkeley.

Prior to joining UH in 2006, Birx spent a decade at New Mexico State University (NMSU) in Las Cruce
'"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
6-Feb-2007


Page: 1 2

Related biology news :

1. Quantum biology -- Powerful computer models reveal key biological mechanism
2. Powerful genome ID method extended to humans
3. Powerful technique for multiplying adult stem cells may aid therapies
4. Powerful X-ray beams at Argonne, new electronic flight simulator
5. Powerful toolkit developed for functional profiling of yeast genes
6. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
7. Saudi Arabias KAUST names WHOI first research partner
8. Multinational research: protecting ecology means understanding people, too
9. Newly created cancer stem cells could aid breast cancer research
10. Carnegie Mellons Peter Adams receives EPA research grant
11. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Powerful ally life sciences research head give keynote

(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: